WEDNESDAY, March 29, 2017 (HealthDay News) -- Exposure to the quadrivalent human papillomavirus (HPV) vaccine during pregnancy is not associated with adverse pregnancy outcomes, according to a study published in the March 30 issue of the New England Journal of Medicine.
Nikolai M. Scheller, M.D., from Statens Serum Institut in Copenhagen, Denmark, and colleagues linked information on vaccination, adverse pregnancy outcomes, and potential confounders in a cohort of women in Denmark with a pregnancy that ended between Oct. 1, 2006, and Nov. 30, 2013. The authors propensity-score matched women who had vaccine exposure during the prespecified time windows with women who did not have vaccine exposure in a 1:4 ratio.
In matched analyses, the researchers found that, compared with no exposure, exposure to the quadrivalent HPV vaccine was not linked to increased risks of major birth defect (prevalence odds ratio, 1.19; 95 percent confidence interval [CI], 0.90 to 1.58), spontaneous abortion (hazard ratio, 0.71; 95 percent CI, 0.45 to 1.14), preterm birth (prevalence odds ratio, 1.15; 95 percent CI, 0.93 to 1.42), low birth weight (prevalence odds ratio, 1.10; 95 percent CI, 0.85 to 1.43), small size for gestational age (prevalence odds ratio, 0.86; 95 percent CI, 0.72 to 1.02), or stillbirth (hazard ratio, 2.43; 95 percent CI, 0.45 to 13.21).
"Quadrivalent HPV vaccination during pregnancy was not associated with a significantly higher risk of adverse pregnancy outcomes than no such exposure," the authors write.
The study was partially funded by the Novo Nordisk Foundation.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
